Roland E. Knoblauch

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial

George D. Demetri, Margaret von Mehren, Robin L. Jones et al. · Journal of Clinical Oncology · 2015 · 809 citations · Full text

Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

Keunchil Park, Eric B. Haura, Natasha B. Leighl et al. · Journal of Clinical Oncology · 2021 · 597 citations · Full text

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

Antonio Passaro, Jing Wang, Yan Wang et al. · Annals of Oncology · 2023 · 347 citations · Full text

Amivantamab plus Chemotherapy in NSCLC with <i>EGFR</i> Exon 20 Insertions

Caicun Zhou, Kejing Tang, Byoung Chul Cho et al. · New England Journal of Medicine · 2023 · 301 citations

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of <i>EGFR</i> Exon 20 Insertion–Driven NSCLC

Jiyeon Yun, Soo‐Hwan Lee, Seok‐Young Kim et al. · Cancer Discovery · 2020 · 272 citations · Full text